参考文献
[1]Timmis A, Vardas P, Townsend N, et al, and the Atlas Writing Group, European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022; 43: 716–99.
[2]Martin SS, Aday AW, Almarzooq ZI, et al, and the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation 2024; 149: e347–913.
[3]Institute for Health Metrics and Evaluation. Gobal Burden of Diseases Viz Hub. Institute for Health Metrics and Evaluation, 2023. https://vizhub.healthdata.org/gbdcompare/(accessed July 1, 2023).
[4]Sidney S, Quesenberry CP Jr, Jaffe MG, et al. Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol 2016; 1: 594–99.
[5]Lopez AD, Adair T. Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. Int J Epidemiol 2019; 48: 1815–23.
[6]Martin SS, Aday AW, Allen NB, et al, and the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation 2025; 151: e41–660.
[7]Conrad N, Molenberghs G, Verbeke G, et al. Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study. BMJ 2024; 385: e078523.
[8]Benfari G, Essayagh B, Michelena HI, et al. Severe aortic stenosis: secular trends of incidence and outcomes. Eur Heart J 2024; 45: 1877–86.
[9]Wu J, Nadarajah R, Nakao YM, et al. Temporal trends and patterns in atrial fibrillation incidence: a population-based study of 3·4 million individuals.Lancet Reg Health Eur 2022; 17: 100386.
[10]Ghelani KP, Chen LY, Norby FL, Soliman EZ, Koton S, Alonso A. Thirty-year trends in the incidence of atrial fibrillation: the ARIC Study. J Am Heart Assoc 2022; 11: e023583.
[11]Sonne-Holm E, Kjærgaard J, Bang LE, Fosbøl E, Carlsen J, Winther-Jensen M. Pulmonary embolism: age specific temporal trends in incidence and mortality in Denmark 1999-2018. Thromb Res 2022; 210: 12–19.
[12]Hwang H-G, Lee JH, Kim S-A, et al. Incidence of venous thromboembolism: the 3rd Korean nationwide study. J Korean Med Sci 2022; 37: e130.
[13]von Kappelgaard L, Gislason G, Davidsen M, Zwisler A-D, Juel K. Temporal trends and socioeconomic differences in the incidence of left-sided valvular heart disease in Denmark. Eur Heart J Qual Care Clin Outcomes 2021; 7: 608–15.
[14]Christensen DM, Strange JE, Phelps M, et al. Age- and sex-specific trends in the incidence of myocardial infarction in Denmark, 2005 to 2021.Atherosclerosis 2022; 346: 63–67.
[15]Chi GC, Kanter MH, Li BH, et al. Trends in acute myocardial infarction by race and ethnicity. J Am Heart Assoc 2020; 9: e013542.
[16]Li L, Scott CA, Rothwell PM. Study on behalf of the OV. Trends in stroke incidence in high-income countries in the 21st century. Stroke 2020; 51: 1372–80.
[17]Madsen TE, Khoury JC, Leppert M, et al. Temporal trends in stroke incidence over time by sex and age in the GCNKSS. Stroke 2020; 51: 1070–76.
[18]Münster AM, Rasmussen TB, Falstie-Jensen AM, et al. A changing landscape: temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006-2015. Thromb Res 2019; 176: 46–53.
[19]Vahanian A, Beyersdorf F, Praz F, et al, and the ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43: 561–632.
[20]Glikson M, Nielsen JC, Kronborg MB, et al, and the ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021; 42: 3427–520.
[21]Visseren FLJ, Mach F, Smulders YM, et al, and the ESC National Cardiac Societies, and the ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227–337.
[22]Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovasculardisease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 2019; 74: e177–232.
[23]Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health 2019; 7: e1020–30.
[24]Gregson J, Kaptoge S, Bolton T, et al, and the Emerging Risk Factors Collaboration. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 2019; 4: 163–73.
[25]Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation.Nat Rev Cardiol 2023; 20: 404–17.
[26]Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Diabetes and aortic aneurysm: current state of the art. Cardiovasc Res 2018; 114: 1702–13.
[27]Nazarzadeh M, Bidel Z, Mohseni H, et al, and the INVENT Consortium. Blood pressure and risk of venous thromboembolism: a cohort analysis of 5.5 million UK adults and mendelian randomization studies. Cardiovasc Res 2023; 119: 835–42.
[28]Liberale L, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation, aging, and cardiovascular disease. J Am Coll Cardiol 2022; 79: 837–47.
[29]Conrad N, Verbeke G, Molenberghs G, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 2022; 400: 733–43.
[30]Giza DE, Iliescu G, Hassan S, Marmagkiolis K, Iliescu C. Cancer as a risk factor for cardiovascular disease. Curr Oncol Rep 2017; 19: 39.
[31]Kraler S, Blaser MC, Aikawa E, Camici GG, Lüscher TF. Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy.Eur Heart J 2022; 43: 683–97.
[32]Trohman RG, Huang HD, Sharma PS. Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1. Front Cardiovasc Med 2023; 10: 1060030.
[33]Trohman RG, Huang HD, Sharma PS. Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 2. Front Cardiovasc Med 2023; 9: 1060096.
[34]Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J 2015; 36: 1536–46.
[35]Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al, and the Peer Review Committee Members. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2022; 146: e334–482.
[36]Jaiswal V, Ang SP, Kumar D, et al. Sodium-glucose cotransporter-2 inhibitors and arrhythmias: a meta-analysis of 38 randomized controlled trials. JACC Adv 2025; 4: 101615.
[37]Shah T, Zhang Z, Shah H,et al. Effect of sodium-glucose cotransporter-2 inhibitors on the progression of aortic stenosis. JACC 2025; 18: 738–48.
[38]Khan SS, Matsushita K, Sang Y, et al, and the Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and validation of the American Heart Association’s PREVENT equations. Circulation 2024; 149: 430–49.
[39]Graham IM, Di Angelantonio E, Visseren F, et al, and the European Society of Cardiology Cardiovascular Risk Collaboration. Systematic coronary risk evaluation (SCORE): JACC focus seminar 4/8. J Am Coll Cardiol 2021; 77: 3046–57
